Merck & Co., Inc: all 2,453 studies
Page 19 of 25. Open to participants first (145), then studies with results posted, then the rest; newest registration first within each.
- Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular AnomaliesNo longer availableNCT03317366
- Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)WithdrawnNCT03221634Phase 2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)WithdrawnNCT03143998Phase 4
- Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)CompletedNCT02996890Phase 1
- A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active, not recruitingNCT02974738Phase 1
- Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida ColonizationCompletedNCT02888197
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2
- A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)CompletedNCT02835118Phase 1
- A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)CompletedNCT02835105Phase 1
- A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) FormulationsCompletedNCT02790840Phase 1
- Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue SamplesCompletedNCT02762721
- RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast InfectionsCompletedNCT02733432Phase 2
- Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)CompletedNCT02684292Phase 3
- Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Active, not recruitingNCT02653118
- A Pharmacokinetics Study of AF-130 in Healthy SubjectsCompletedNCT02652936Phase 1
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
- PT2385-102 Food Effect Study of PT2385 in Healthy VolunteersCompletedNCT02553356Phase 1
- An Ascending Multiple Dose Study of CD101 IV in Healthy SubjectsCompletedNCT02551549Phase 1
- The Effects of RPL554 on Top of Standard COPD Reliever MedicationsCompletedNCT02542254Phase 2
- A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)TerminatedNCT02532868Phase 1
- A Single Ascending Dose Study of CD101 IV in Healthy SubjectsCompletedNCT02516904Phase 1
- Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy SubjectsCompletedNCT02508753Phase 1
- Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal ImpairmentTerminatedNCT02508740Phase 1
- A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) FormulationsCompletedNCT02492776Phase 1
- A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)CompletedNCT02477514Phase 1
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedNCT02476955Phase 1
- Comparison of RPL554 With Placebo and Salbutamol in Asthmatic PatientsCompletedNCT02427165Phase 2
- Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)WithdrawnNCT02410590Phase 4
- Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1TerminatedNCT02387125Phase 1
- A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344)WithdrawnNCT02364752Phase 1
- SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsCompletedNCT02307162Phase 1
- A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)WithdrawnNCT02303782Phase 1/2
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Active, not recruitingNCT02293980Phase 1
- A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)CompletedNCT02269735Phase 1
- Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)CompletedNCT02269059Phase 1
- A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)CompletedNCT02229877Phase 1
- Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)WithdrawnNCT02204475Phase 3
- Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)CompletedNCT02194608Not applicable
- A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)WithdrawnNCT02180295Phase 3
- Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)CompletedNCT02174159Phase 1
- Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)CompletedNCT02161510Phase 1
- Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1CompletedNCT02122861Phase 1
- Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected SubjectsTerminatedNCT02112942Phase 1
- Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)No longer availableNCT02083484
- A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell CarcinomaCompletedNCT02035657Phase 1
- A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic CancerCompletedNCT02015416Phase 1
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)CompletedNCT02012166Phase 1
- Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)WithdrawnNCT01979510Phase 3
- A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)WithdrawnNCT01926002Phase 1
- Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)CompletedNCT01919125Phase 1
- Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)CompletedNCT01907724Phase 1
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)CompletedNCT01860729Phase 3
- Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)CompletedNCT01852604Phase 2
- Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)TerminatedNCT01841684Phase 3
- The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)WithdrawnNCT01832103Phase 1
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)CompletedNCT01824238Phase 3
- To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)CompletedNCT01813552Phase 1
- Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)CompletedNCT01813513Phase 1
- A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)WithdrawnNCT01770223Phase 4
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)CompletedNCT01760460Phase 3
- A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)WithdrawnNCT01727271Phase 4
- A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid TumorsStatus unknownNCT01724320Phase 1
- 3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting AntiviralsTerminatedNCT01721265
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)CompletedNCT01717300Phase 3
- A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)CompletedNCT01650727Phase 1
- Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)WithdrawnNCT01641666Phase 3
- A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)WithdrawnNCT01626794Phase 3
- A Phase 1, Open-Label, 10 Day Safety StudyCompletedNCT01623401Phase 1
- A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)TerminatedNCT01614782Phase 1
- ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)CompletedNCT01600079
- A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)CompletedNCT01593735Phase 1
- Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)WithdrawnNCT01590225Phase 3
- A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)CompletedNCT01580228Phase 3
- A Phase 1 Crossover Study of Blood Pressure and Heart Rate ResponseCompletedNCT01577459Phase 1
- Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)CompletedNCT01567813
- A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)TerminatedNCT01554189Phase 1
- Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)WithdrawnNCT01552122Phase 3
- Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)WithdrawnNCT01547312Phase 1
- A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine ChallengeCompletedNCT01539473Phase 1
- A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])CompletedNCT01537757Phase 1
- Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)CompletedNCT01508156Phase 1/2
- Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)WithdrawnNCT01500707Phase 1
- Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly SubjectsCompletedNCT01496677Phase 1
- A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])CompletedNCT01496170Phase 1
- Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)CompletedNCT01477580Phase 1
- Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaCompletedNCT01473095Phase 1
- A Thorough QT Study of TR-701free Acid (FA) in Healthy SubjectsCompletedNCT01461460Phase 1
- A Pharmacokinetics and Safety Study in Subjects With Renal ImpairmentCompletedNCT01452828Phase 1
- A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)CompletedNCT01451619Phase 1
- Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male SubjectsCompletedNCT01442831Phase 1
- Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)CompletedNCT01436578
- Study of ACE-536 in Healthy Postmenopausal WomenCompletedNCT01432717Phase 1
- A PK and Safety Study in Subjects With Hepatic ImpairmentCompletedNCT01431833Phase 1
- Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)CompletedNCT01431547Phase 1
- Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic RhinitisCompletedNCT01382654Phase 2
- A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)TerminatedNCT01381731Phase 2
- Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)TerminatedNCT01381666Phase 2
- A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)CompletedNCT01379300Phase 1
- Post Marketing Surveillance Study of CuprimineNo longer availableNCT01374282